The National Institutes of Health (NIH) announced today that it is investing $248.7 million in new technologies to address challenges with COVID-19 testing. The “Rapid Acceleration of Diagnostics” (RADx) initiative awarded contracts to seven biomedical diagnostic companies to support lab-based and point-of-care tests that could significantly increase the number, type and availability of tests by […]
Here’s a roundup of companies announcing new distribution deals.
San Francisco-based Fluidigm priced its offering of about 5.6 million shares of its common stock at $13.50 per share — the bottom of its range — and raised $75 million.
Fluidigm Corp., a San Francisco-based genomic device maker, hopes to go public.
The company, which attempted its first IPO during the thick of the financial crisis, earlier this month filed a shelf registration with the Securities & Exchange Commission for an initial public offering worth $86 million.